https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-first-patient-dosed-in-phase-ib-proof-of-concept-copd-study-of-bbt002-reinforcing-bispecific-pipeline-momentum-302653951.html
/PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology &...
bambusa therapeuticsphase ibannouncesfirstpatient
https://www.jonesday.com/en/practices/experience/2024/10/bambusa-therapeutics-develops-global-patent-portfolios-for-bispecific-antibodies-to-treat-immunological-and-inflammatory
Jones Day represents Bambusa Therapeutics, Inc. in developing global patent portfolios related to various bispecific antibodies for the treatment of...
bambusa therapeuticspatent portfoliosbispecific antibodiesdevelopsglobal